DZWatch Exclusive: A leading medical journal has sparked debate over the safety of several common medications. A newly released list identifies 108 drugs as having limited benefits compared to their potential risks, suggesting they should be withdrawn or used with extreme caution beginning in 2026.
The list includes medications widely available in Algeria, some even sold without prescription, raising concerns about their impact on public health. Among the highlighted drugs are Smecta, commonly used for intestinal disorders; Maxilase, intended to relieve sore throat pain; Toplexil, an anti-cough syrup; and Vogalene, prescribed for dizziness. The inclusion of these familiar names has triggered discussion about their potential dangers, especially given their widespread use.
Health experts emphasize that the classification does not necessarily mean these drugs pose an immediate threat to everyone who has used them. They explain that the recommendations for withdrawal or caution stem from preventative healthcare measures, either due to potential side effects or a lack of significant effectiveness compared to the risks, especially when safer alternatives exist. Experts further stressed that excessive medication use, particularly without medical consultation, may be more dangerous than the drug itself.
“Prudent and rational use is key,” says a local pharmacist. “Patients should not simply follow trends or popular treatments without consulting a doctor.”
Currently, there are no specific treatment protocols for individuals who have previously used these medications, pending official data from relevant health authorities or the World Health Organization. However, experts strongly advise against discontinuing any prescribed medication without consulting a physician.
The medical journal indicates that its 2026 list encompasses 108 drugs, including 89 that are commonly available in France. These medications cover a broad range of treatments and highlight the need for ongoing vigilance regarding drug safety and efficacy.
